ED Medications: Cialis, Levitra, Viagra

Goserelin: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., goserelin) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Granisetron: (Moderate) Concomitant use of vardenafil and granisetron may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Grapefruit juice: (Major) Grapefruit and grapefruit juice should be avoided during treatment with vardenafil orally disintegrating tablets due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; grapefruit juice is a moderate CYP3A4 inhibitor. Guaifenesin; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.

Warnings & Precautions

Lorcaserin: (Moderate) Lorcaserin is a serotonin 2C receptor agonist, and priapism is a potential effect of 5-HT2C receptor agonism. Because there is little experience with the combination of lorcaserin and medications indicated for erectile dysfunction (e.g., phosphodiesterase inhibitors), combined use should be approached with caution. Macimorelin: (Major) Concomitant use of vardenafil and macimorelin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Maprotiline: (Moderate) Concomitant use of vardenafil and maprotiline may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Halogenated Anesthetics: (Major) Concomitant use of vardenafil and halogenated anesthetics increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Haloperidol: (Moderate) Concomitant use of vardenafil and haloperidol may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The intravenous route may carry a higher risk for haloperidol-induced QT/QTc prolongation than other routes of administration. Histrelin: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., histrelin) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consistent with their known effects on the nitric oxide/cGMP pathway, concomitant use of phosphodiesterase inhibitors and nitrates can cause severe hypotension, syncope, or myocardial infarction. Deaths have been reported in men who were using sildenafil while taking nitrate or nitrite therapy for angina. Hydroxychloroquine: (Major) Concomitant use of hydroxychloroquine and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Hydroxyzine: (Moderate) Concomitant use of vardenafil and hydroxyzine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ibutilide: (Major) Concomitant use of vardenafil and ibutilide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Idelalisib: (Major) Do not use vardenafil orally disintegrating tablets with idelalisib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; idelalisib is a strong CYP3A4 inhibitor. Iloperidone: (Major) Concomitant use of vardenafil and iloperidone increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

Product	Dosage	Quantity + Bonus	Price
Levitra Original	20mg	34 + 2 Pills	188.51€ 179.53€	Buy
Levitra Generic	10mg	90 + 8 Pills	150.58€ 143.41€	Buy
Levitra Generic	20mg	90 + 8 Pills	180.78€ 172.17€	Buy
Levitra Generic	60mg	270 + 10 Pills	714.53€ 680.50€	Buy
Levitra Generic	10mg	360 + 10 Pills	407.94€ 388.51€	Buy
Levitra Generic	20mg	30 + 4 Pills	70.59€ 67.23€	Buy
Levitra Soft Tabs	20mg	30 + 2 Pills	99.17€ 94.45€	Buy
Levitra Generic	20mg	60 + 6 Pills	131.11€ 124.87€	Buy
Levitra Generic	40mg	360 + 10 Pills	704.99€ 671.42€	Buy
Levitra Generic	60mg	90 + 6 Pills	291.82€ 277.92€	Buy
Levitra Generic	40mg	10 Pills	41.37€ 39.40€	Buy
Levitra Professional	20mg	360 + 6 Pills	914.63€ 871.08€	Buy
Levitra Generic	40mg	270 + 10 Pills	561.89€ 535.13€	Buy
Levitra Soft Tabs	20mg	360 + 20 Pills	682.21€ 649.72€	Buy
Levitra Professional	20mg	60 + 2 Pills	223.11€ 212.49€	Buy
Levitra Generic	40mg	60 + 4 Pills	162.37€ 154.64€	Buy

Imatinib: (Major) Do not use vardenafil orally disintegrating tablets with imatinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; imatinib is a moderate CYP3A4 inhibitor. Indinavir: (Major) Do not use vardenafil orally disintegrating tablets with indinavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; indinavir is a strong CYP3A4 inhibitor. Inotuzumab Ozogamicin: (Major) Concomitant use of vardenafil and inotuzumab increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

What is Levitra, and how does it work?

Lopinavir; Ritonavir: (Major) Concomitant use of vardenafil and lopinavir increases the risk of QT/QTc prolongation and torsade de pointes (TdP). (Major) Do not use vardenafil orally disintegrating tablets with ritonavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; ritonavir is a strong CYP3A4 inhibitor. Coadministration of ritonavir with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax. Concomitant use may increase the risk of vardenafil-related adverse effects, such as prolonged erection or QT prolongation. Isavuconazonium: (Major) Do not use vardenafil orally disintegrating tablets with isavuconazonium due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Itraconazole: (Major) Do not use vardenafil orally disintegrating tablets with itraconazole due to increased vardenafil exposure. Vardenafil is primarily metabolized by CYP3A4/5; itraconazole is a strong CYP3A4 inhibitor. If coadministration of itraconazole and vardenafil oral tablets is required, the maximum single vardenafil dose is 5 mg every 24 hours in patients receiving itraconazole 200 mg daily; for patients receiving itraconazole 400 mg daily, the maximum single vardenafil dose is 2.5 mg every 24 hours. In addition, both itraconazole and vardenafil have been associated with QT prolongation; coadministration may increase this risk. Ketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Concomitant use may also increase the exposure of vardenafil, further increasing generic levitra 24 h buy the risk for adverse effects, such as hypotension and syncope.

• Levitra may interact with other medications like alpha-blockers for prostate issues.
• Use caution when combining Levitra with other vasodilators.
• Patients should avoid excessive alcohol when taking Levitra to prevent adverse effects.
• It is important to stay hydrated and avoid dehydration during treatment.
• Levitra's effectiveness can be reduced by certain health conditions, like obesity.
• Men with certain eye conditions should have medical clearance before use.
• Levitra may cause dizziness; patients should stand slowly from sitting or lying.
• Overdose symptoms include prolonged erections and cardiovascular symptoms; seek immediate help.

If concomitant use of ketoconazole and vardenafil oral tablets is required, the maximum single vardenafil oral tablet dose is 5 mg every 24 hours for patients receiving ketoconazole 200 mg daily and 2.5 mg every 24 hours for patients receiving ketoconazole 400 mg daily. Do not use vardenafil orally disintegrating tablets (ODTs) with ketoconazole. Coadministration with ketoconazole increased the AUC of vardenafil by 10-fold.

What should I tell my doctor before they prescribe Levitra?

Leuprolide: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monit oring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Leuprolide; Norethindrone: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levofloxacin: (Moderate) Concomitant use of levofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP).

Patient resources

Lithium: (Moderate) Concomitant use of vardenafil and lithium may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lonafarnib: (Major) Do not use vardenafil orally disintegrating tablets with lonafarnib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; lonafarnib is a strong CYP3A4 inhibitor. Loperamide: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Loperamide; Simethicone: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lansoprazole; Amoxicillin; Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Lapatinib: (Moderate) Concomitant use of vardenafil and lapatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lefamulin: (Major) Coadministration of lefamulin tablets is contraindicated with vardenafil due to increased vardenafil exposure which may result in QT prolongation and torsade de pointes (TdP).

• Levitra can improve quality of life for men with erectile dysfunction.
• The medication has a high success rate in restoring erectile function.
• Certain foods and beverages can influence Levitra's effectiveness.
• The medication is generally well tolerated but requires professional oversight.
• Levitra's rapid onset makes it convenient for spontaneous sexual activity.
• Side effects can sometimes indicate allergic reactions requiring immediate attention.
• Levitra is part of a broader treatment plan, including lifestyle changes.
• Always inform your doctor of any side effects or concerns during treatment.

Avoid use of lefamulin injection with vardenafil; however, if coadministration of lefamulin injection cannot be avoided, ECG monitoring is recommended during treatment. Vardenafil is a primary CYP3A4 substrate that is associated with QT prolongation. Both therapeutic and supratherapeutic doses of vardenafil can produce an increase in QTc interval. Lefamulin is a moderate CYP3A4 inhibitor that has a concentration-dependent QTc prolongation effect. Coadministration of vardenafil with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. Lenacapavir: (Major) Do not use vardenafil orally disintegrating tablets with lenacapavir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.

Medication Class	Potential Interaction	Effect
Nitrates	Dangerous hypotension	Should not be combined
Alpha-blockers	Lower blood pressure	May cause orthostatic hypotension
CYP3A4 inhibitors	Increased Levitra levels	Risk of side effects
Antifungal agents (e.g., ketoconazole)	Increased drug levels	Potential toxicity

Vardenafil is primarily metabolized by CYP3A; lenacapavir is a moderate CYP3A inhibitor. Lenvatinib: (Major) Concomitant use of vardenafil and lenvatinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Letermovir: (Major) Do not use vardenafil orally disintegrating tablets with letermovir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; letermovir is a moderate CYP3A4 inhibitor. Leuprolide: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

• Levitra is approved for the treatment of erectile dysfunction in men over 18.
• It is not recommended for use in women or children.
• The medication is usually taken orally, in tablet form.
• Levitra's effectiveness relies on sexual stimulation to initiate an erection.
• Adverse effects are typically mild but can include dizziness and upset stomach.
• Consult your healthcare provider if you experience prolonged or painful erections.
• Levitra should be used cautiously in men with liver or kidney disease.
• Always disclose your complete medical history to ensure safe use.

Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monit oring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Leuprolide; Norethindrone: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levofloxacin: (Moderate) Concomitant use of levofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

A community-based knowledge platform for medical professionals

Goserelin: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., goserelin) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Granisetron: (Moderate) Concomitant use of vardenafil and granisetron may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Grapefruit juice: (Major) Grapefruit and grapefruit juice should be avoided during treatment with vardenafil orally disintegrating tablets due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; grapefruit juice is a moderate CYP3A4 inhibitor. Guaifenesin; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.

What are the serious side effects of vardenafil?

Halogenated Anesthetics: (Major) Concomitant use of vardenafil and halogenated anesthetics increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Haloperidol: (Moderate) Concomitant use of vardenafil and haloperidol may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The intravenous route may carry a higher risk for haloperidol-induced QT/QTc prolongation than other routes of administration. Histrelin: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., histrelin) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consistent with their known effects on the nitric oxide/cGMP pathway, concomitant use of phosphodiesterase inhibitors and nitrates can cause severe hypotension, syncope, or myocardial infarction.

Professional resources

Deaths have been reported in men who were using sildenafil while taking nitrate or nitrite therapy for angina. Hydroxychloroquine: (Major) Concomitant use of hydroxychloroquine and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Hydroxyzine: (Moderate) Concomitant use of vardenafil and hydroxyzine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ibutilide: (Major) Concomitant use of vardenafil and ibutilide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Idelalisib: (Major) Do not use vardenafil orally disintegrating tablets with idelalisib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Lithium: (Moderate) Concomitant use of vardenafil and lithium may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lonafarnib: (Major) Do not use vardenafil orally disintegrating tablets with lonafarnib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; lonafarnib is a strong CYP3A4 inhibitor. Loperamide: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Loperamide; Simethicone: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Explore the many benefits of joining Sermo's medical community

Do not use vardenafil orally disintegrating tablets (ODTs) with ketoconazole. Coadministration with ketoconazole increased the AUC of vardenafil by 10-fold. Lansoprazole; Amoxicillin; Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Lapatinib: (Moderate) Concomitant use of vardenafil and lapatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lefamulin: (Major) Coadministration of lefamulin tablets is contraindicated with vardenafil due to increased vardenafil exposure which may result in QT prolongation and torsade de pointes (TdP).

Is Levitra or Viagra better?

Avoid use of lefamulin injection with vardenafil; however, if coadministration of lefamulin injection cannot be avoided, ECG monitoring is recommended during treatment. Vardenafil is a primary CYP3A4 substrate that is associated with QT prolongation. Both therapeutic and supratherapeutic doses of vardenafil can produce an increase in QTc interval. Lefamulin is a moderate CYP3A4 inhibitor that has a concentration-dependent QTc prolongation effect. Coadministration of vardenafil with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold.

What is tadalafil (Cialis®)?

Lenacapavir: (Major) Do not use vardenafil orally disintegrating tablets with lenacapavir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A; lenacapavir is a moderate CYP3A inhibitor. Lenvatinib: (Major) Concomitant use of vardenafil and lenvatinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Letermovir: (Major) Do not use vardenafil orally disintegrating tablets with letermovir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; letermovir is a moderate CYP3A4 inhibitor. Lopinavir; Ritonavir: (Major) Concomitant use of vardenafil and lopinavir increases the risk of QT/QTc prolongation and torsade de pointes (TdP). (Major) Do not use vardenafil orally disintegrating tablets with ritonavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; ritonavir is a strong CYP3A4 inhibitor. Coadministration of ritonavir with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax. Concomitant use may increase the risk of vardenafil-related adverse effects, such as prolonged erection or QT prolongation. Lorcaserin: (Moderate) Lorcaserin is a serotonin 2C receptor agonist, and priapism is a potential effect of 5-HT2C receptor agonism.

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Vardenafil is primarily metabolized by CYP3A4/5; idelalisib is a strong CYP3A4 inhibitor. Iloperidone: (Major) Concomitant use of vardenafil and iloperidone increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Imatinib: (Major) Do not use vardenafil orally disintegrating tablets with imatinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; imatinib is a moderate CYP3A4 inhibitor. Indinavir: (Major) Do not use vardenafil orally disintegrating tablets with indinavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets.

Is Cialis stronger than Viagra?

Vardenafil is primarily metabolized by CYP3A4/5; indinavir is a strong CYP3A4 inhibitor. Inotuzumab Ozogamicin: (Major) Concomitant use of vardenafil and inotuzumab increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Isavuconazonium: (Major) Do not use vardenafil orally disintegrating tablets with isavuconazonium due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Itraconazole: (Major) Do not use vardenafil orally disintegrating tablets with itraconazole due to increased vardenafil exposure. Vardenafil is primarily metabolized by CYP3A4/5; itraconazole is a strong CYP3A4 inhibitor.

Join the online physician networking revolution now

If coadministration of itraconazole and vardenafil oral tablets is required, the maximum single vardenafil dose is 5 mg every 24 hours in patients receiving itraconazole 200 mg daily; for patients receiving itraconazole 400 mg daily, the maximum single vardenafil dose is 2.5 mg every 24 hours. In addition, both itraconazole and vardenafil have been associated with QT prolongation; coadministration may increase this risk. Ketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Concomitant use may also increase the exposure of vardenafil, further increasing generic levitra 24 h buy the risk for adverse effects, such as hypotension and syncope. If concomitant use of ketoconazole and vardenafil oral tablets is required, the maximum single vardenafil oral tablet dose is 5 mg every 24 hours for patients receiving ketoconazole 200 mg daily and 2.5 mg every 24 hours for patients receiving ketoconazole 400 mg daily. Because there is little experience with the combination of lorcaserin and medications indicated for erectile dysfunction (e.g., phosphodiesterase inhibitors), combined use should be approached with caution. Macimorelin: (Major) Concomitant use of vardenafil and macimorelin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Maprotiline: (Moderate) Concomitant use of vardenafil and maprotiline may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.